Nakauchi, Masaya
Vos, Elvira L.
Tang, Laura H.
Gonen, Mithat
Janjigian, Yelena Y.
Ku, Geoffrey Y.
Ilson, David H.
Maron, Steven B.
Yoon, Sam S.
Brennan, Murray F.
Coit, Daniel G.
Strong, Vivian E.
Article History
Received: 22 January 2021
Accepted: 5 March 2021
First Online: 8 April 2021
Disclosures
: Yelena Y. Janjigian has received research funding from Rgenix, Boehringer Ingelheim, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly, and Merck and served on advisory boards for Rgenix, Merck Serono, Bristol-Myers Squibb, Eli Lilly, Pfizer, Bayer, Imugene, Merck, Daiichi-Sankyo, and AstraZeneca. Geoffrey Y. Ku has received honoraria and research funding from Merck, Bristol-Myers Squibb, and Pieris, and research funding from AstraZeneca, Zymeworks, and Daiichi Sankyo. David H. Ilson has received research funding from and served on advisory boards for Astellas, Eli Lilly, Pieris, and Taiho, and has served on advisory boards for Astra-Zeneca, Amgen, Bayer, Bristol-Myers Squibb, and Roche. Steven B. Maron has received research funding from Genentech and Guardant Health and has served on advisory boards for Natera and Basileahas. All the disclosed funding was provided to the institution for other studies. All the other authors declare that they have no financial relationships to disclose.